Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ERYTECH Pharma S A : Webinar on Eryaspase in Pancreatic Cancer (September 1, 2021)

09/03/2021 | 08:22am EDT

Presentation on the lead product candidate eryaspase, L-asparaginase encapsulated in donor-derived red blood cells, featured by KOLs and also the Principal Investigators of the TRYbeCA-1 and rESPECT studies, respectively; Dr. Manuel Hidalgo Medina, M.D., Ph.D., Weill Cornell Medicine/NewYork-Presbyterian Hospital, and Dr. Marcus Noel, M.D., Georgetown University.

Access the replay of the conference

Disclaimer

ERYTECH Pharma SA published this content on 01 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 September 2021 12:21:04 UTC.


ę Publicnow 2021
All news about ERYTECH PHARMA S.A.
12:09pEuropean ADRs 0.3% Lower Wednesday as Equinor, Rio Tinto Retreat
MT
10/26JMP Securities Downgrades ERYTECH Pharma to Market Perform From Market Outperform
MT
10/26Cowen Downgrades ERYTECH Pharma to Market Perform From Outperform
MT
10/25NASDAQ 100 : Top Midday Decliners
MT
10/25European ADRs Move Lower in Monday Trading
MT
10/25ERYTECH PHARMA S A : ▪The prespecified subgroup of patients treated with eryaspase a..
PU
10/25GLOBAL MARKETS LIVE : HSBC, PayPal, Tesla, Daimler, Intel...
10/25Wall Street Sees Cautiously Higher Open Ahead of Busy Week for Tech Earnings; FB Earnin..
MT
10/25Health Care Stocks Mixed Premarket Monday
MT
10/25ERYTECH PHARMA S A : Health Care
MT
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 7,95 M 9,21 M 9,21 M
Net income 2021 -63,0 M -73,0 M -73,0 M
Net Debt 2021 16,1 M 18,7 M 18,7 M
P/E ratio 2021 -0,72x
Yield 2021 -
Capitalization 78,7 M 91,3 M 91,3 M
EV / Sales 2021 11,9x
EV / Sales 2022 5,89x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 2,82 €
Average target price 12,40 €
Spread / Average Target 340%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-60.34%91
GILEAD SCIENCES, INC.16.25%84 921
BIONTECH SE258.67%70 618
WUXI APPTEC CO., LTD.23.63%64 231
REGENERON PHARMACEUTICALS22.57%61 565
VERTEX PHARMACEUTICALS-22.12%47 753